期刊文献+

新型抗结核药物筛选的分子靶位研究进展 被引量:3

下载PDF
导出
摘要 1新型抗结核药物研发的意义。1.1抗结核药物研发的必要性和紧迫性:至少有下面5条理由说明新型抗结核药物研究的必要性和紧迫性:
作者 张宗德 马玙
出处 《结核病与胸部肿瘤》 2005年第3期160-165,共6页 Tuberculosis and Thoracic Tumor
  • 相关文献

参考文献10

  • 1Scientific blueprint for TB drug development, the Global Alliance for TB Drug Development forum. 2001,1-52.
  • 2Andries K, Verhasseh P, Guilemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science, 2005, 307(5707):223-227.Epub 2004 Dec 9.
  • 3Igarashi M, Nakagawa N, Hattori S, et al. Caprazamycin A-F, novel anti-TB antibiotics from Streptomyces sp. (C)Abstr.42nd ICAAC,ASM.Washington,DC. Sept.2002:p.232.
  • 4Stover CK, Warrener P, VanDevanter DR, et al. A small molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature,2000,405(6789): 962-969.
  • 5McCune RM, Tompsett R ,McDermott. Fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. J.Exp.Med,1956,104:763-801.
  • 6Cole ST. Comparative mycobactefial genomics as a tool for drug target and antigen discovery. Eur Respir J, 2000,20Suppl.36:78s-86s.
  • 7MeKinney JD. In vivo veritas: the search for TB drug targets goes live. Nature Medieine,2000,6(12):1330-1333.
  • 8Segal W, Bloch H. Biochemical differentiation of Mycobacterium tuberculosis grown in vivo and in vitro. J Bcteriol,1956, 72:132-141.
  • 9Berthet FX. Attenuation of virulence by disruption of the Mycobacterium tuberculosis erp gene. Science,1998,282:759-762.
  • 10Glickman MS, Cox JS,Jocob WR Jr. A novel mycolic acid cycloprapane synthetase is required for ceding,persistence,and vindence of Mycobacterium tuberculosis. Mol Cell,2000,5:717-727.

同被引文献33

  • 1孙冰梅,车志宏.结核分枝杆菌耐药的分子机制及耐药基因检测方法的研究进展[J].山西医药杂志,2005,34(4):301-303. 被引量:13
  • 2江山,朱道银,骆旭东,蒋英,陈全.结核分枝杆菌DNA疫苗对小鼠结核病免疫治疗作用的实验研究[J].中华结核和呼吸杂志,2005,28(5):305-309. 被引量:18
  • 3刘伟,司书毅,肖春玲.新型抗结核药物的研究进展[J].国外医药(抗生素分册),2006,27(2):91-95. 被引量:8
  • 4吴雪琼,郑越,徐燕杰,张俊仙,陆阳,张灵霞,史迎昌,李洪敏,韩永,曹立雪,李忠明.不同剂量结核病DNA疫苗及细胞因子联合免疫的研究[J].中国免疫学杂志,2006,22(10):883-888. 被引量:5
  • 5AMIT N,RAHUL J. Recent advances in new structural classes of anti-tuberculosis agents[ J]. Cult Med Chem,2005 ,12(16) :1873 - 1886.
  • 6ANDRIES K, JOZEF L, MARCEL K, et al. Quinoline derivatives for the treatment of latent tuberculosis: WO ,2006/7048 A1 [ P]. 2006 - 06 - 29.
  • 7JANIN Y L. Antituberculosis drugs: ten years of research [ J ]. Bioorg Med Chem, 2007, 15 ( 7 ) : 2479 - 2513.
  • 8TSUBOUCHI H, SASAKI H, HARAGUCHI Y, et al. Antituberculous activity of a novel series of optically active 6-nitro-2,3-dihydroimidazo [ 2,1 -b ] oxazoles [ J ]. Antirnicrob Agents Chemother, 2005,49 (1) :16- 19.
  • 9WANG J H,ELCHERT B ,HUI Y,et al. Synthesis of trehalose-based compounds and their inhi-bitory activities against Mycobacterium smegmatis [ J]. Bioorg Med Chem,2004,12(24) :6397 -6413.
  • 10AHMED K K, SRINIVASA R S, KALEEM A M, et al. Anti-tubercular agents. Part 3. Benzothiadiazine as a novel scaffold for anti-Mycobacterium activity [ J ]. Bioorg Med Chem,2006,14 (3) :650 - 658.

引证文献3

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部